GLP 1 Less Common and Serious Side Effects: 1
Retatrutide Retatrutide, triple-agonist (GIP/GLP-1/Glucagon)
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
If anything, it only helped me be more aware of the goal
Mounjaro is a weekly injectable weight-loss drug for adults with obesity or overweight plus another weight-related condition
The titration schedule from TRIUMPH-4 started all participants at 2 mg once weekly